These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23663749)

  • 1. Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.
    Molfenter T; Kim JS; Quanbeck A; Patel-Porter T; Starr S; McCarty D
    Implement Sci; 2013 May; 8():50. PubMed ID: 23663749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The payer's role in addressing the opioid epidemic: It's more than money.
    Molfenter T; McCarty D; Jacobson N; Kim JS; Starr S; Zehner M
    J Subst Abuse Treat; 2019 Jun; 101():72-78. PubMed ID: 31174716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio.
    Molfenter T; Sherbeck C; Starr S; Kim JS; Zehner M; Quanbeck A; Jacobson N; McCarty D
    J Addict Med; 2018; 12(2):85-91. PubMed ID: 29176511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).
    D'Onofrio G; Edelman EJ; Hawk KF; Pantalon MV; Chawarski MC; Owens PH; Martel SH; VanVeldhuisen P; Oden N; Murphy SM; Huntley K; O'Connor PG; Fiellin DA
    Implement Sci; 2019 May; 14(1):48. PubMed ID: 31064390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.
    Melnick ER; Nath B; Dziura JD; Casey MF; Jeffery MM; Paek H; Soares WE; Hoppe JA; Rajeevan H; Li F; Skains RM; Walter LA; Patel MD; Chari SV; Platts-Mills TF; Hess EP; D'Onofrio G
    BMJ; 2022 Jun; 377():e069271. PubMed ID: 35760423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.
    Andrews CM; D'Aunno TA; Pollack HA; Friedmann PD
    Med Care Res Rev; 2014 Feb; 71(1):43-60. PubMed ID: 24051897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.
    Molfenter T; Fitzgerald M; Jacobson N; McCarty D; Quanbeck A; Zehner M
    J Psychoactive Drugs; 2019; 51(3):272-279. PubMed ID: 30732542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.
    Wallack SS; Thomas CP; Martin TC; Chilingerian J; Reif S
    J Behav Health Serv Res; 2010 Jan; 37(1):64-78. PubMed ID: 18668369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
    Ober AJ; Watkins KE; Hunter SB; Ewing B; Lamp K; Lind M; Becker K; Heinzerling K; Osilla KC; Diamant AL; Setodji CM
    BMC Fam Pract; 2017 Dec; 18(1):107. PubMed ID: 29268702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice Predictors of Buprenorphine Prescribing by Family Physicians.
    Peterson LE; Morgan ZJ; Borders TF
    J Am Board Fam Med; 2020; 33(1):118-123. PubMed ID: 31907252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
    Knudsen HK; Abraham AJ; Johnson JA; Roman PM
    J Subst Abuse Treat; 2009 Oct; 37(3):307-12. PubMed ID: 19577406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
    Yang JC; Roman-Urrestarazu A; Brayne C
    PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.